1. Home
  2. XWEL vs ACXP Comparison

XWEL vs ACXP Comparison

Compare XWEL & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

XWEL

XWELL Inc.

N/A

Current Price

$0.41

Market Cap

5.9M

ML Signal

N/A

Logo Acurx Pharmaceuticals Inc.

ACXP

Acurx Pharmaceuticals Inc.

N/A

Current Price

$1.05

Market Cap

5.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
XWEL
ACXP
Founded
2006
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9M
5.8M
IPO Year
2010
2021

Fundamental Metrics

Financial Performance
Metric
XWEL
ACXP
Price
$0.41
$1.05
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $10.33
AVG Volume (30 Days)
33.3K
★ 94.2K
Earning Date
12-01-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
★ $29,210,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.26
$0.90
52 Week High
$2.20
$7.54

Technical Indicators

Market Signals
Indicator
XWEL
ACXP
Relative Strength Index (RSI) 23.65 46.16
Support Level $0.33 $0.95
Resistance Level $0.50 $1.12
Average True Range (ATR) 0.07 0.09
MACD -0.01 0.01
Stochastic Oscillator 31.60 62.81

Price Performance

Historical Comparison
XWEL
ACXP

About XWEL XWELL Inc.

XWELL Inc is an international wellness organization dedicated to delivering restorative and health-focused services to travelers through its three reportable operating segments: XpresSpa, XpresTest, and Naples Wax Center. The XpresSpa segment, which generates maximum revenue, operates spa service locations in airports, offering massage, skincare, and travel products. The XpresTest segment provides aircraft wastewater and passenger nasal sampling through the CDC's bio-surveillance program. The Naples Wax Center segment operates six locations offering face and body waxing, skincare services, and cosmetic products. The Company generates maximum revenue from the United States.

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

Share on Social Networks: